Abstract:The effect and potential molecular mechanisms of berberine on gluconeogenesis in skeletal muscles and adipose tissues were investigated. After adaptive feeding for one week, 8 rats were randomly selected as the normal group and fed on a standard diet. The remaining 32 rats were fed on a high-fat diet and given an intravenous injection of streptozotocin (STZ) for 2 weeks to induce the diabetic models. The diabetic rat models were confirmed by oral glucose tolerance test (OGTT) and randomly divided into 4 groups (n=8 each), which were all fed on a high-fat diet. Berberine (3 g/kg per day) or metformin (183 mg/kg per day) was intragastrically administered to the diabetic rats for 12 weeks, serving as berberine group and metformin group respectively. 5-aminoimidazole-4-carboxamide1-β-D-ribofuranoside [AICAR, an agonist of AMP-activated protein kinase (AMPK), 0.5 mg/kg per day] was subcutaneously injected to the diabetic rats for 12 weeks, serving as AICAR group. The remaining 8 diabetic rats served as the model group, which was given a 0.5% carboxyl methylcellulose solution by oral gavage. Fasting serum insulin (FINS), OGTT as well as lipid parameters were tested by commercial kit. The protein levels of liver kinase B1 (LKB1), AMPK, phosphorylated AMP-activated protein kinase (p-AMPK), transducer of regulated CREB activity 2 (TORC2), phosphorylated transducer of regulated CREB activity 2 (p-TORC2), phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-phosphatase (G6Pase) in skeletal muscles and adipose tissues were examined by Western blotting. The results showed that berberine significantly decreased the body weight, plasma glucose, insulin levels, and homeostatic model assessment for insulin resistance (HOMA-IR) of diabetic rats compared with those in the model group. Meanwhile, the serum total triglyceride (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) levels were markedly decreased and high-density lipoprotein cholesterol (HDL-C) level was significantly increased after the treatment with berberine. In addition, we found that berberine significantly increased the expression of p-AMPK and LKB1, while decreasing the p-TORC2 levels in skeletal muscles and adipose tissues. Moreover, the expression of PEPCK and G6Pase was significantly down-regulated after the treatment with berberine compared to the model group. It was suggested that the mechanism by which berberine inhibited peripheral tissue gluconeogenesis may be attributed to the activation of the LKB1-AMPK-TORC2 signaling pathway.

Berberine chloride ameliorated PI3K/Akt-p/SIRT-1/PTEN signaling pathway in insulin resistance syndrome-induced rats

[Effect of Berberine on the Insulin Resistance and TLR4/IKKbeta/NF-kappaB Signaling Pathways in Skeletal Muscle of Obese Rats with Insulin Resistance]

Chronic Effects of Berberine on Blood, Liver Glucolipid Metabolism and Liver PPARs Expression in Diabetic Hyperlipidemic Rats

Protective Effects of Berberine on High Fat-Induced Kidney Damage by Increasing Serum Adiponectin and Promoting Insulin Sensitivity.

Berberine Ameliorates High-fat-induced Insulin Resistance in HepG2 Cells by Modulating PPARs Signaling Pathway

Berberine Improves Inflammatory Responses of Diabetes Mellitus in Zucker Diabetic Fatty Rats and Insulin-Resistant HepG2 Cells through the PPM1B Pathway

Effect of Berberine on Endoplasmic Reticulum Stress and Insulin Resistance in Skeletal Muscle of Metabolic Syndrome Rats and Its Mechanism

Berberine Improves Hepatic Insulin Resistance by Activating the SIRT1/Opa1 Pathway: an in Vitro and in Vivo Study

Effects of Berberine on Glucose and Lipid Metabolism in Animal Experiment

Berberine Inhibits Gluconeogenesis in Skeletal Muscles and Adipose Tissues in Streptozotocin-induced Diabetic Rats via LKB1-AMPK-TORC2 Signaling Pathway

Ameliorative Effect of Berberine on Endothelial Dysfunction in Diabetic Rats Induced by High-Fat Diet and Streptozotocin

Berberine hydrochloride-loaded lipid-based nanoparticles ameliorate β-cell function by targeting Nrf2/NF-κB signaling pathway in alloxan-induced diabetes using a murine model: Optimization through full factorial design

Effects of berberine hydrochloride on nonalcoholic fatty liver disease in rats

Berberine Ameliorates Hyperglycemia In Alloxan-Induced Diabetic C57bl/6 Mice Through Activation Of Akt Signaling Pathway

Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome

Pomegranate Peel Polyphenols Alleviate Insulin Resistance Through the Promotion of Insulin Signaling Pathway in Skeletal Muscle of Metabolic Syndrome Rats

Berberine Ameliorates Renal Impairment and Inhibits Podocyte Dysfunction by Targeting the Phosphatidylinositol 3‐kinase–protein Kinase B Pathway in Diabetic Rats

Berberine mitigates hepatic insulin resistance by enhancing mitochondrial architecture via the SIRT1/Opa1 signalling pathway

Effects of Berberine on Hepatic Sirtuin 1-Uncoupling Protein 2 Pathway in Non-alcoholic Fatty Liver Disease Rats Induced by High-fat Diet

Effect of Berberine on the HPA-axis Pathway and Skeletal Muscle GLUT4 in Type 2 Diabetes Mellitus Rats

Lipid-lowering effect of berberine in human subjects and rats